

CEIPI

Advanced Training Program

Regulatory
Affairs
and Intellectual
Property
Protection in the
Pharmaceutical
Industry



24

25

26

Septembre 2026



Center for International

Intellectual Property Studies | CEIPI

University of Strasbourg

1. Concept of the studies

The development, authorisation and commercialisation of medicinal products in the pharmaceutical sector are amongst the most regulated and complex areas of European Union (EU) law. The legal framework governing the regulation of medicinal products can affect a broad range of private rights, intellectual property law, competition law and consumer law. In particular, patents, supplementary protection certificates (SPCs) and regulatory rewards, notably regulatory data protection, constitute a sophisticated legal framework of overlapping exclusivities that impacts both innovation and competition. This complexity creates challenges for experts tasked with understanding a rapidly evolving legal and regulatory landscape.

The CEIPI Advanced Training Program on Regulatory Affairs and Intellectual Property Protection in the Pharmaceutical Industry, now in its sixth edition, is a unique educational proposal targeting regulatory and intellectual property professionals in the pharmaceutical sector. The three days of intensive training revolve around the intersections of patent and regulatory law. In this respect, issues such as SPCs and regulatory data protection, amongst other relevant topics, will be taught by leading legal professionals and experts in the field.

This interactive course aims to provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations as well as on the patent and SPC related landscape. It will create a space for discussion on how to interpret and apply legislation in this sector in light of new developments. These developments include an overview of the current state of the European Commission's proposals for the revision of the EU pharmaceutical legislation and of the SPC legislation.



Case studies and discussion sessions throughout the program will help participants to explore options and strategies for key regulatory activities and to provide an opportunity to share experiences with our expert trainers and other delegates. The program also gives opportunities for informal discussion with the speakers and other participants.

CEIPI offers a professional certificate for successful participation in this advanced training program.

2. Prospective participants

This program is addressed to regulatory professionals, patent attorneys and in-house lawyers, as well as public servants working in public health organizations, who frequently have to navigate through the several legal domains of relevance even if they are just trained in one. For this year's edition, we hope to expand our attendees to include a broader range of participants, including representatives from national regulatory agencies, innovators in the generics sector, and business development experts.

3. Program duration

The advanced training program has a total duration of 18 hours, distributed in three days:

- Thursday September 24, 9:00-12:45 and 14:00-18:00
- Friday September, 25, 9:00-12:30 and 13:45-18:00
- Saturday September 26, 9:00-13:00



Thursday September 24

The Interface between Regulatory and IP Exclusivities: Regulatory Data Protection and the Role of Marketing Authorisations

This module focuses on the protection that may be accorded to data and information submitted for the granting of certain types of marketing authorisations for medicinal products for human use. The pharmaceutical dossier, the types of information protected, key concepts, the duration of the protection and acts against which information is protected will be discussed. The approach of the European Medicines Agency (EMA) towards reactive and proactive transparency, including, the manner in which it handles data and information pertaining to medicinal products will be discussed and analysed.

Topics include:

- The EU centralised procedure for obtaining marketing authorisations (MAs) for medicinal products for human use
- The framework of regulatory data protection
- The legislation, internal policies and case law which inform EMA's approach towards transparency
- How to enforce and challenge regulatory data protection
- Interface between regulatory data protection and competition law



COURSE LAYOUT - DAY 1

Time CET	Topic	Speakers
8.45 – 9.00	Welcome coffee	
9.00 – 9.30	Opening and Introduction	<ul style="list-style-type: none"> -Yann Basire, Director General and Associate Professor at CEIPI -Thomas Lemieux, Associate Professor, CEIPI -Peter Thomsen, President of EPI, Independent Consultant at ATEXIPS -Pierick Rousseau, Former Intellectual Property Director at Pierre Fabre -Alexander Meier, Life Sciences Regulatory Partner at Morgan, Lewis & Bockius LLP
9.30 – 10.30	The grant of marketing authorisations (MAs) for medicinal products and its importance for exclusivity rights	Alexander Meier
10.30 – 10.45 Coffee break		
10.45 – 12.45	Regulatory data protection for medicinal products	Alexander Meier
12.45 – 14.00 Lunch break		
14.00 – 15.30	The EMA's approach to transparency: between legislation, internal policies and case-law	Representative of the European Medicines Agency (EMA)
15.30 – 16.00 Coffee break		
16.00 – 17.00	How to enforce and how to challenge regulatory data protection in daily practice	Alexander Meier
17.00 – 18.00	Outlook on the future of regulatory data protection	Alexander Meier

Friday September 25

Supplementary Protection Certificates (SPCs) and Practical Cases

This module explores the legislative background and litigation strategies concerning Supplementary Protection Certificates (SPCs) in the European Union. Participants will become familiarized with timelines, where to apply for SPCs, substantive requirements, and the scope of protection during the term of protection awarded by an SPC. Controversial areas, such as which is the product protected by the basic patent and the relationship between SPCs and patent claims drafting, will also be explored in this session.

Topics include:

- ◆ The SPC legal framework
- ◆ The interface between competition law and SPCs
- ◆ Patent claims and SPCs
- ◆ Strategies to obtain and challenge SPC protection
- ◆ Manufacture for export waiver



COURSE LAYOUT - DAY 2

Time CET	Topics	Speaker
8.45 - 9.00	Welcome coffee	
9.00 - 9.30	General Legal Framework	Pierick Rousseau
9.30 - 10.45	Conditions for an SPC	Peter Thomsen
10.45 - 11.15 Coffee break		
11.15 - 12.00	Filing and granting procedure	Anne Boutaric, European and French Patent Attorney at Germain Maureau
12.00 - 12.30	Term of protection	Anne Boutaric
12.30 - 13.45 Lunch break		
13.45 - 14.30	Scope of protection	Pierick Rousseau
14.30 - 15.30	Enforcement and revocation of SPCs	Peter Thomsen
15.30 - 16.00 Coffee break		
16.00 - 16.45	Strategic considerations on SPCs	Peter Thomsen
16.45 - 17.15	Outlook for the future of SPCs	Peter Thomsen Anne Boutaric
17.15 - 18.00	Roundtable Discussion with Practical Cases and Q&A	Peter Thomsen, Pierick Rousseau, Alexander Meier, Anne Boutaric
18.00 - 19.00 Cocktail		

Saturday September 26

Orphan Market Exclusivity and Paediatric Extensions

The final day is devoted to orphan market exclusivity and paediatric exclusivity extensions. Orphan market exclusivity in terms of its nature, effects, and interaction with other exclusivities will be discussed, along with conditions for applying for paediatric extensions. Lecturers will address aspects such as how to obtain orphan market exclusivity, situations of mixed orphan/non-orphan indications for the same active pharmaceutical ingredient, the scope of orphan drugs exclusivity, and enforcement (strategies for breaking protection).

Topics include:

- ♦ Award of orphan market exclusivity
- ♦ Situations of mixed orphan/non-orphan indications for the same active substance
- ♦ How to enforce and challenge orphan market exclusivity
- ♦ Applying for and obtaining paediatric extension to an SPC



COURSE LAYOUT - DAY 3

Time CET	Topic	Speakers
8.45 - 9.00	Welcome coffee	
9.00 - 11.00	Orphan market exclusivity and Outlook	Alexander Meier
11.00 - 11.15 Coffee Break		
11.15 - 12.45	Paediatric Extensions and Outlook	Peter Thomsen
12.45 - 13.00	Closing	Peter Thomsen Pierick Rousseau Alexander Meier Anne Boutaric Thomas Lemieux

Practical information

This program has been jointly designed and directed by:

- Peter Thomsen, President of EPI, Independent consultant at ATEIPS
- Alexander Meier, Life Sciences Regulatory Partner at Morgan, Lewis & Bockius LLP
- Pierick Rousseau, Former Intellectual Property Director at Pierre Fabre
- Anne Boutaric, European and French Patent Attorney at Germain Maureau
- Thomas Lemieux, Lecturer in Law, CEIPI, University of Strasbourg

Fees:

1 720 €- Early bird before 30 June 2026

1 920 € Full fee for all registrations after 30 June 2026

675€ TTC Fee for students

For more information, please contact:

→ Email: pharma-seminar@ceipi.edu

Administrative Assistant: Rita Gardosi, gardosi@ceipi.edu

Course Direction: Thomas LEMIEUX, CEIPI Training Lead, t.lemieux@ceipi.edu

Location:

CEIPI

Université de Strasbourg

Bâtiment LE CARDO

7 rue de l'Ecarlate

CS 20024

FR-67082 STRASBOURG Cedex

